TO THE EDITOR
I read with interest the review on the retinoic acid (RA) syndrome by Tallman.
1 Although the role of RA in the treatment of acute promyelocytic leukemia (APL) have been shown extensively, RA syndrome is a serious complication observed in some patients with APL . In order to prevent RA syndrome, administration of high-dose corticosteroids have been proven to be a very effective treatment approach. However, important questions have been raised by Tallman whether the prophylactic corticosteroid treatment is hazardous and whether there should be a trial to address the effects of steroids on outcome.
In various studies, it has been shown that certain steroid hormones (dexamethasone (Dex), prednisolone) are among the most effective agents that induce differentiation of mouse myeloid leukemic cells to macrophages and granulocytes. In addition, we have shown that short-course (3-5 days) high-dose methylprednisolone (20-30 mg/kg/day) treatment can induce in vivo differentiation of leukemic cells in children with APL and in other subtypes of AML (FAB AML-MI, -M2, -M4, -M7).
2-4 Futhermore, Dex has been shown to promote the expression of chemotactic peptide receptors and chemotactic activity in differentiating HL-60 cells induced by RA and a human T-cell-derived lymphokine. 5 Moreover, Dex markedly potentiates the RA-induced differentiation of HL-60 cells to neutrophils. 6 Interestingly, the synergistic effect of Dex and RA on differentiation and proliferation of human megakaryoblastic leukemia cell line (HIMeg) has also been reported. 7 Furthermore, de Ridder et al 8 investigated whether Dex would antagonize the beneficial effects of all-trans RA. The in vitro experiments of this study showed that Dex did not inhibit the RA-induced differentiation and proliferation arrest of t(15;17) NB4 cells, but rather showed antiproliferative activity itself. The results of these studies suggest that combined short-course high-dose steroid and RA could be more effective in the treatment of APL. Furthermore, addition of steroid may reduce RA doses to be used that might be effective in preventing RA toxicity.
Although the mechanisms of effect of corticosteroids on APL cells are unclear, steroid hormone is thought to be effective on responsive leukemic cells via binding to steroid receptors, which initiate a variety of signaling cascades. HL-60 cells have glucocorticoid (GC) receptors that are homologus to RA, vitamin D3 and thyroid hormone receptors. The GC receptors in HlMeg cells have been shown to be upregulated by RA in vitro. 7 More recently, it has also been demonstrated that during differentiation of HL-60 cells by methylprednisolone or arsenic trioxide (A 2 O 3 ) different signal transduction pathways are used. 9 In contrast to A 2 O 3 , methylprednisolone-induced differentiaton of HL-60 cells was associated with serine/threonine protein phosphatases type 2A regulatory subunit upregulation.
In conclusion, these results suggest that RA combined with highdose steroid could be a promising treatment approach for patients with APL especially for those refractory to retinoids. G Hiçsö nmez 
